Skip to content
Ds-1062
Ds-1062 is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD00228955412
Breast neoplasmsD001943EFO_0003869C502236
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Triple negative breast neoplasmsD064726334
Colorectal neoplasmsD015179122
Ovarian neoplasmsD010051EFO_0003893C56122
Endometrial neoplasmsD016889EFO_0004230122
Stomach neoplasmsD013274EFO_0003897C16122
HemangiosarcomaD00639411
Prostatic neoplasmsD011471C61111
Pancreatic neoplasmsD010190EFO_0003860C25111
Urinary bladder neoplasmsD001749C67111
Uterine cervical neoplasmsD002583111
Show 4 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDS-1062
INNdatopotamab deruxtecan
Description
Ds-1062 is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Classification
Unknown
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL4297939
ChEBI ID
PubChem CID
DrugBank
UNII IDGD2OWY1DTK (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 75 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details